Trial · NCT06607107
mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
NCT06607107, Phase 2, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria. Trials, record NCT06607107. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06607107
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
- NCT number
- NCT06607107
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 29 participants, estimated
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Interventions
- mFOLFOX7 combined with Camrelizumab and apatinib
- First posted
- 2024-09-23
- Last updated
- 2024-09-23
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Major pathological response (MPR) rate | 6 months | MPR rate is defined as the proportion of participants with =\<10% residual viable tumor in the tumor bed at the time of surgery, as assessed by central pathological review. |
| Secondary | Objective Response Rate(ORR) by RECIST 1.1 | 6 months | ORR is the proportion of patients who achieved a complete or partial response during or after treatment |
| Secondary | pathologic complete response (pCR) rate | 6 months | pCR is the proportion of surgical specimens with no tumor lesion or only carcinoma in situ. |
| Secondary | Duration of remission(DOR) by mRECIST | 12 months | DOR is the time between the first assessment of the tumor as a complete or partial response and the first assessment as tumor progression or death. |
| Secondary | Disease Control Rate(DCR) by mRECIST | 6 months | DCR is the proportion of all patients who have tumors that shrink or remain stable and stay that way for a certain period of time. |
| Secondary | Disease-free-survival(DFS) by RECIST 1.1 | 12 months | DFS is the time from the beginning of radical surgery to the first recurrence of the tumor and metastasis or death of patient for any reason. |
| Secondary | Progression-Free Survival (PFS) by RECIST 1.1 | 12 months | PFS is intended to be the time during or after treatment when there is no disease progression. |
| Secondary | Overall Survival (OS) by RECIST 1.1 | 24 months | OS is from the point at which treatment begins or the disease is diagnosed to the time at which the patient dies. |
| Secondary | Progression-Free Survival rate (PFSR) by RECIST 1.1 | 12 months | PFSR is the proportion of progression-free survival patients. |
| Secondary | Overall Survival Rate (OSR) by RECIST 1.1 | 24 months | OSR is the proportion of all surviving patients. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06607107
GET https://conductscience.org/api/trials/v1/NCT06607107/registered